Acumen Pharmaceuticals (ABOS) Total Liabilities (2020 - 2026)

Acumen Pharmaceuticals (ABOS) has 7 years of Total Liabilities data on file, last reported at $46.2 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 5.73% year-over-year to $46.2 million; the trailing twelve-month figure through Mar 2026 stood at $46.2 million (down 5.73% YoY), and the FY2025 full-year result was $52.4 million, down 8.35% from the prior year.
• Total Liabilities slipped to $46.2 million in Q1 2026, from $52.4 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $57.2 million in Q4 2024 to a low of $4.0 million in Q1 2022.
• A 5-year average of $31.3 million and a median of $43.2 million in 2023 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities soared 716.22% in 2024 and slipped 8.35% in 2025, its largest moves.
• Tracing ABOS's Total Liabilities over 5 years: stood at $7.8 million in 2022, then soared by 452.38% to $43.2 million in 2023, then soared by 32.5% to $57.2 million in 2024, then slipped by 8.35% to $52.4 million in 2025, then slipped by 11.93% to $46.2 million in 2026.
• Business Quant data shows ABOS's Total Liabilities at $46.2 million in Q1 2026, $52.4 million in Q4 2025, and $49.0 million in Q3 2025.